Adagio Therapeutics, Inc.
(NASDAQ : ADGI)

( )
ADGI After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Commercial Services » Miscellaneous Commercial Services
symbolcompany%chnglast%shortavg$volume
ETSYEtsy, Inc. -5.95%212.357.5%$394.47m
EFXEquifax, Inc. -2.15%256.842.0%$184.31m
CRLCharles River Laboratories International, Inc. -3.36%417.934.5%$174.10m
CPRTCopart, Inc. -3.80%141.144.4%$152.32m
MRVIMaravai Lifesciences Holdings, Inc. -3.57%47.270.0%$124.12m
RELYRemitly Global, Inc. -7.07%38.100.8%$119.73m
FLTFLEETCOR Technologies, Inc. -1.28%266.853.6%$111.93m
CHGGChegg, Inc. -3.38%69.6613.1%$100.36m
CLVTClarivate Plc -3.25%22.040.0%$99.45m
TALTAL Education Group -3.03%4.480.7%$88.80m
FOURShift4 Payments, Inc. -3.83%82.210.0%$87.46m
STMPStamps.com, Inc. 0.03%329.4023.6%$85.72m
BRBroadridge Financial Solutions, Inc. -0.50%167.401.5%$74.40m
TASKTaskUs, Inc. -6.39%63.970.0%$68.64m
PGNYProgyny, Inc. -8.40%55.830.0%$63.22m

Company Profile

Adagio Therapeutics, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren? Russo and Laura Walker on June 3, 2020 and is headquartered in Waltham, MA.